Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction?

Clinica Chimica Acta

Volumn 443, Issue , 2015, Pages 9-16

  Pouleur, Anne Catherine ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Biomarkers; Heart failure; Natriuretic peptides

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN RECEPTOR; NATRIURETIC FACTOR; SOLUBLE ST2 PROTEIN; TROPONIN; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DYSPNEA; EXTRACELLULAR MATRIX; GOLD STANDARD; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE INJURY; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; PEPTIDE ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; HEART STROKE VOLUME; PATHOPHYSIOLOGY;

BIOMARKERS; HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 84924244475     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.10.046     Document Type: Article

References (76)

1. Jessup M., Brozena S. Heart failure. N Engl J Med 2003, 348(20):2007-2018.
2. Go A.S., Mozaffarian D., Roger V.L., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129(3):399-410.
3. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. ESC Committee for Practice Guidelines. Eur J Heart Fail 2012, 14(8):803-869.
4. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115(8):949-952.
5. Tang W.H., Francis G.S., Morrow D.A., et al. National Academy of Clinical Biochemistry Laboratory Medicine. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007, 116(5):e99-e109.
6. van Kimmenade R.R.J., Januzzi J. Emerging biomarkers in heart failure. Clin Chem 2012, 58:127-138.
7. Pascual-Figal D.A., Ordoñez-Llanos J., Tornel P.L., et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54(23):2174-2179.
8. Januzzi J.L. Natriuretic peptides as biomarkers in heart failure. J Investig Med 2013, 61(6):950-955.
9. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994, 90:195-203.
10. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993, 87:464-469.
11. Nakagawa O., Ogawa Y., Itoh H., et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995, 96:1280-1287.
12. Maeda K., Tsutamota T., Wada A., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998, 135:825-832.
13. Sudoh T., Kangawa K., Minamino N., et al. A new natriuretic peptide in porcine brain. Nature 1988, 332(6159):78-81.
14. Green S.M., Martinez-Rumayor A., Gregory S.A., et al. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 2008, 168(7):741-748.
15. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Breathing not properly multinational study investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347(3):161-167.
16. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002, 106(4):416-422.
17. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004, 350:647-654.
18. Moe G.W., Howlett J., Januzzi J.L., et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007, 115(24):3103-3110.
19. Januzzi J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005, 95(8):948-954.
20. Maisel A., Mueller C., Adams K., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008, 10:824-839.
21. Wang T.J., Larson M.G., Levy D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002, 90:254-258.
22. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002, 40:976-982.
23. Daniels L.B., Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 2007, 50:2357-2368.
24. Logeart D., Thabut G., Jourdain P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004, 43(4):635-641.
25. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
26. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-FeFT). Circulation 2003, 107:1278-1283.
27. Januzzi J.L., Rehman S., Mueller T., et al. Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. Clin Chem 2010, 56(12):1814-1821.
28. Di Angelantonio E., Chowdhury R., Sarwar N., et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120:2177-2187.
29. Cheng V.L., Krishnaswamy P., Kazanegra R., et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure. J Am Coll Cardiol 2001, 37:386-391.
30. Bettencourt P., Azevedo A., Pimenta J., et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004, 110(15):2168-2174.
31. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002, 105:2392-2397.
32. Doust J.A., Pietrzak E., Dobson A., Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005, 330:625-627.
33. Januzzi J.L., Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013, 127(4):500-507.
34. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 2007, 49:1733-1739.
35. Shah M.R., Claise K.A., Bowers M.T., et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am Heart J 2005, 150:893-898.
36. Gaggin H.K., Mohammed A.A., Bhardwaj A., et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail 2012, 18(8):626-634.
37. Lainchbury J.G., Troughton R.W., Strangman K.M., et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009, 55(1):53-60.
38. Felker G.M., Hasselblad V., Hernandez A.F., et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158(3):422-423.
39. Eggers K.M., Venge P., Lind L. Mid-regional pro-atrial natriuretic peptide levels in the elderly: clinical and prognostic implications, and comparison to B-type natriuretic peptides. Clin Chim Acta 2013, 419:62-66.
40. von Haehling S., Jankowska E.A., Morgenthaler N.G., et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007, 50:1973-1980.
41. Moertl D., Berger R., Struck J., et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 2009, 53(19):1783-1789.
42. Maisel A., Mueller C., Nowak R., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55:2062-2076.
43. Shah R.V., Truong Q.A., Gaggin H.K., et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012, 33(17):2197-2205.
44. Palmer S.C., Prickett T.C., Espiner E.A., et al. Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension 2009, 54:612-618.
45. Sangaralingham S.J., Huntley B.K., Martin F.L., et al. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic peptide. Hypertension 2011, 57(2):201-207.
46. Lok D.J., Klip I.T., Voors A.A., et al. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail 2014, 16(9):958-966.
47. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989, 258:301-304.
48. Shah R.V., Chen-Tournoux A.A., Picard M.H., et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009, 2:311-319.
49. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50:607-613.
50. Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated. Eur J Heart Fail 2011, 13:718-725.
51. Gruson D., Lepoutre T., Ahn S.A., Rousseau M.F. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol 2014, 172(1). [Epub 2014 Jan 4].
52. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
53. Weinberg E.O., Shimpo M., Hurwitz S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
54. Kempf T., Eden M., Strelau J., et al. The transforming growth factor-beta superfamily member growth differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006, 98:351-360.
55. Xu J., Kimball T.R., Lorenz J.N., et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006, 98:342-350.
56. Kempf T., von Haehling S., Peter T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007, 50(11):1054-1060.
57. Anand I.S., Kempf T., Rector T.S., et al. Serial measurement of growth differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010, 122:1387-1395.
58. Logeart D., Beyne P., Cusson C., et al. Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. Am Heart J 2001, 141:247-253.
59. Horwich T.B., Patel J., MacLellan W.R., et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003, 108:833-838.
60. Peacock W., De Marco T., Fonarow G.C., et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008, 358:2117-2126.
61. Sato Y., Yamada T., Taniguchi R., et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001, 103:369-374.
62. Peacock W.F., De Marco T., Fonarow G.C., et al. ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008, 358(20):2117-2126.
63. Latini R., Masson S., Anand I.S., et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
64. Masson S., Anand I., Favero C., et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 2012, 125(2):280-288.
65. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110(19):3121-3128.
66. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217-1224.
67. de Boer R.A., Voors A.A., Muntendam P., et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11(9):811-817.
68. Shah R.V., Chen-Tournoux A.A., Picard M.H., et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12(8):826-832.
69. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43(1):60-68.
70. Yancy C.W., Jessup M., Bozkurt B., et al. ACCF/AHA Guideline for the Management of Heart Failure. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62(16):e147-e239.
71. Ky B., French B., Levy W.C., Sweitzer N.K. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5:183-190.
72. Manzano-Fernández S., Boronat-Garcia M., Albaladejo-Otón M.D., et al. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol 2009, 103(12):1753-1759.
73. Lutsey P.L., Alonso A., Selvin E., et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J Am Heart Assoc 2014, 3(3):e000936.
74. Udell J.A., Morrow D.A., Jarolim P., et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol 2014, 63(22):2421-2428.
75. Kestenbaum B., Sachs M.C., Hoofnagle A.N., et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 2014, 7(3):409-417.
76. Gruson D., Lepoutre T., Ketelslegers J.M., et al. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 2012, 37(2):258-262.